Ipsen S.A. (IPSEY) Discusses Phase II LANTIC Data and Innovation in Engineered Neuroinhibitors for Aesthetic Indications Transcript
Ipsen S.A. – Evolution of the composition of the Board of Directors
Annual General Meeting of Ipsen S.A. held on 13 May 2026
Ipsen S.A. (IPSEY) Q1 2026 Earnings Call Transcript
IPSEN (OTCMKTS:IPSEY) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales
Ipsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript
IPSEN (OTCMKTS:IPSEY) Shares Gap Up – What’s Next?
IPSEN (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average – Time to Sell?
IPSEN (OTCMKTS:IPSEY) Shares Pass Above 200 Day Moving Average – What’s Next?
Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)
Ipsen S.A. - Initiation of the share buy-back program
Ipsen S.A. - Annual General Meeting held on 21 May 2025
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
Ipsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript
Ipsen S.A. (IPSEY) Q4 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi
GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis
Annual General Meeting of Ipsen S.A. held on 28 May 2024
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.'s Annual General Meeting on 28 May 2024
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
2 More Potential Biotech Buyout Targets
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
US FDA approves Ipsen's rare bone disorder drug
US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
Ipsen S.A. publishes its 2023 Half-Year Financial Report
Ipsen S.A. (IPSEY) Q4 2022 Earnings Call Transcript
Ipsen S.A.'s (IPSEY) CEO David Loew on Q2 2022 Results - Earnings Call Transcript
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology
Ipsen S.A. (IPSEY) CEO David Loew on Q4 2021 Results - Earnings Call Transcript
Ipsen S.A. (IPSEY) CEO Francesco Caio on Q2 2021 Results - Earnings Call Transcript
Ipsen illustre son engagement envers les patients en oncologie avec un nombre record d’abstracts à présenter lors du congrès virtuel de l’ESMO 2020
Ipsen : Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer | MarketScreener
Ipsen : rejoint une collaboration clinique pour évaluer le cabozantinib (CABOMETYX®) associé à l'atezolizumab dans le cancer du poumon et dans le cancer de la prostate métastatique | Zone bourse
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer
Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy